Evidence map›Paper›PMID 42146683›Full record

ArticlebioRxiv : the preprint server for biology2026

Mannosylated nanoparticle immunogens enhance the circumsporozoite protein-specific B cell response and improve protection against sporozoite challenge.

Courtney E McDougal, Mark D Langowski, Daria Nikolaeva, Chengbo Chen, Derek J Bangs, Adian Valdez, Rashmi Ravichandran, Suna Cheng, Mariah Lofgren, Marlon Dillon and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Courtney E McDougalDepartment of Immunology, University of Washington, Seattle, WA, USA.ORCID 0000-0003-1607-5931
Mark D LangowskiInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID 0000-0002-0777-598X
Daria NikolaevaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Chengbo ChenDepartment of Medicinal Chemistry, University of Washington, WA, USA.
Derek J BangsDepartment of Immunology, University of Washington, Seattle, WA, USA.ORCID 0009-0005-9408-5774
Adian ValdezInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Rashmi RavichandranInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Suna ChengInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Mariah LofgrenVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Marlon DillonVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Delante SandersVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Alvaro Molina-CruzLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Azza H IdrisThe Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard University, Cambridge, MA, USA.
Kazutoyo MiuraVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kelly LeeDepartment of Medicinal Chemistry, University of Washington, WA, USA.
Robert A SederVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Marion PepperDepartment of Immunology, University of Washington, Seattle, WA, USA.ORCID 0000-0001-7278-0147
Neil P KingInstitute for Protein Design, University of Washington, Seattle, WA, USA.

Funding

Acquisition of BD FACSymphony A3 Lite Flow CytometerS10OD024979 · OD · UNIVERSITY OF WASHINGTON · PI BLACK, MICHELE C · 2020 to 2020
$344k
Understanding and overcoming Plasmodium-specific immune evasion mechanismsF32AI178963 · NIAID · UNIVERSITY OF WASHINGTON · PI MCDOUGAL, COURTNEY · 2024 to 2025
$157k
NIAID NIH HHS F32 AI178963NIH HHS S10 OD024979
6 · The paper itself

Abstract

Underprocessed oligomannose glycans on protein nanoparticle immunogens engage the innate immune system through mannose-binding lectin and complement, enhancing immunogen trafficking and B cell responses. However, the extent to which oligomannose glycans directly improve protective immunity has remained unclear. Here we generate a series of CSP-bearing I53-50 nanoparticle malaria vaccine candidates with defined numbers and types of engineered N-linked glycans and systematically evaluate their immunogenicity and protective efficacy. Oligomannose display enhanced early plasmablast and germinal center B cell responses, leading to increased CSP-specific memory B cells, long-lived plasma cells, and durable serum antibody titers. Furthermore, nanoparticles bearing oligomannose glycans conferred the strongest protection against sporozoite challenge. By comparing immunogens with defined glycoforms, we attribute improved immune responses and protection specifically to oligomannose rather than complex or truncated glycans. These results will help guide the development of general strategies for glycan engineering aimed at enhancing the protective efficacy of nanoparticle vaccines.

Identifiers

PMID42146683
PMCPMC13174426

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.